Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma
Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA
3 Jul 2020
The paediatric precision oncology study INFORM: Clinical outcome and benefit for...
Dr Cornelis van Tilburg - Hopp Children's Cancer Center Heidelberg, Heidelberg, ...
30 May 2020
COVID-19: Managing paediatric patients under the COVID pandemic
Dr Carmen Ballestas - Memorial Healthcare System, Florida, Miami
4 May 2020
Updates in treating NTRK fusion cancer: Highlights from ESMO 2019
Prof Marc Peeters and Prof Jesus Garcia-Foncillas
9 Mar 2020
Indian Pediatric Oncology Group (InPOG)
Dr. Ramandeep Arora - Max Institute of Cancer Care, Saket, New Delhi, India
20 Feb 2020
Outcomes in paediatric oncology: Are we closing the gap between LMICs and high-i...
Prof Laila Hessissen - Mohammed V University of Rabat, Rabat, Morocco
7 Feb 2020
CAR-T cell therapy for ALL: Current challenges and future approaches
Dr Sara Ghorashian - University College London, London, UK
23 Jan 2020
CART-T cell therapy in young patients with relapsed/refractory ALL
Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany
23 Jan 2020
The role of blinatumomab followed by HSCT in paediatric patients with ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
23 Jan 2020
Long-term toxicities in paediatric ALL
Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark
23 Jan 2020
Frontline therapy of ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
23 Jan 2020
BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
23 Jan 2020
